New combo therapy shows promise for hard-to-treat leukemia

NCT ID NCT04848974

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether adding the drug uproleselan to standard chemotherapy (cladribine and low-dose cytarabine) could help people with treated secondary acute myeloid leukemia (AML). Secondary AML is a type of leukemia that develops after treatment for another bone marrow disease. The study enrolled 37 adults and aimed to find the best dose and measure how many patients achieved remission. The goal is to improve outcomes for this difficult-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: uproleselan, cladribine, and low-dose cytarabine
What this could lead to: If successful, this combination could offer a new treatment option for patients with secondary AML that has returned after prior therapy.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to all patients. The added drug may also increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.